NORIA THERAPEUTICS
Noria is a research and development company managed by experienced radiopharmaceutical development leaders and focused on the development of novel targeted alpha therapeutics and theranostic agents.
NORIA THERAPEUTICS
Industry:
Therapeutics
Address:
New York, New York, United States
Country:
United States
Status:
Active
Similar Organizations
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
More informations about "Noria Therapeutics"
Bayer acquires Noria and PSMA Therapeutics to …
Jun 3, 2021 · Through this acquisition Bayer will obtain exclusive rights to a differentiated alpha radionuclide therapy based on actinium-225 and a small molecule targeting prostate-specific membrane antigen (PSMA).See details»
Noria Therapeutics - Crunchbase Company Profile & Funding
Noria is a research and development company managed by experienced radiopharmaceutical development leaders and focused on the development of novel targeted alpha therapeutics …See details»
Bayer props up sagging radionuclide business with Noria acquisition
2 days ago · Bayer has agreed to buy Noria Therapeutics and its subsidiary PSMA Therapeutics, adding to its pipeline of radionuclide drugs for cancer as sales of its lead product in the …See details»
Bayer Acquires Noria, PSMA Therapeutics to Expand Place in
Jun 4, 2021 · On Thursday, Bayer announced an agreement to acquire Noria Therapeutics Inc. and PSMA Therapeutics Inc. in an effort to expand the global biopharmaceutical company’s …See details»
Bayer Acquires Noria and PSMA Therapeutics to Expand Pipeline …
Jun 3, 2021 · The companies acquired by Bayer, Noria and PSMA Therapeutics, have exclusive world-wide rights to technology licensed from Weill Cornell Medicine (New York, NY, USA) …See details»
Bayer acquires Noria Therapeutics - 2021-06-03 - Crunchbase
Jun 3, 2021 · Noria Therapeutics Noria is a research and development company managed by experienced radiopharmaceutical development leaders. Acquiring Organization: Bayer Bayer …See details»
Bayer acquires Noria and PSMA Therapeutics to …
Jun 4, 2021 · The German Pharmaceutical company Bayer has announced that it’s about to close a deal to acquire Noria Therapeutics and PSMA Therapeutics, two small bio-scientific companies built around radiotherapy research from …See details»
Bayer Strengthens Oncology Portfolio with Noria and PSMA …
Bayer entered into an agreement to acquire Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc., obtaining exclusive rights to a differentiated alpha radionuclide …See details»
Bayer Acquires Noria, PSMA Therapeutics - PharmaLive
Jun 4, 2021 · On Thursday, Bayer announced an agreement to acquire Noria Therapeutics Inc. and PSMA Therapeutics Inc. in an effort to expand the global biopharmaceutical company’s portfolio of targeted alpha radionuclide …See details»
Bayer : Acquires Noria and PSMA Therapeutics to Expand Pipeline …
Jun 3, 2021 · Bayer today announced that it has entered into an agreement to acquire Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc. Through this acquisition, Bayer will …See details»
Bayer acquires Noria and PSMA Therapeutics to expand pipeline in ...
Through this acquisition, Bayer will obtain exclusive rights to a differentiated alpha radionuclide investigational compound based on actinium-225 and a small molecule directed towards...See details»
Noria Therapeutics - Drug pipelines, Patents, Clinical trials - Synapse
Pluvicto has raked in more than $700 million, and Novartis expects it to become a multibillion-dollar drug, CEO Vas Narasimhan said during an investor call in October 2023. Also, in June …See details»
Bayer Acquires Noria and PSMA Therapeutics to Expand Pipeline …
Jun 3, 2021 · Bayer Acquires Noria and PSMA Therapeutics to Expand Pipeline in Prostate Cancer The purchases broaden Bayer’s existing oncology portfolio of targeted alpha …See details»
Bayer Acquires to Expand Prostate Cancer Pipeline
Broadening its existing oncology portfolio of targeted alpha therapies (TATs), Bayer said it plans to acquire Noria Therapeutics and PSMA Therapeutics, thereby obtaining exclusive worldwide …See details»
Bayer picks up radiotherapeutics biotech to prop up dwindling …
Jun 3, 2021 · Amid sliding sales for prostate cancer drug Xofigo, Bayer will bolster its portfolio of targeted alpha therapies with the acquisition of radiotherapeutics biotech Noria Therapeutics …See details»
Bayer Acquires Noria and PSMA Therapeutics to Expand Pipeline …
Jun 4, 2021 · Through this acquisition, Bayer will obtain exclusive rights to a differentiated alpha radionuclide investigational compound based on actinium-225 and a small molecule directed …See details»
Bayer Inks Pharma Acquisition Deal to Advance Cancer Therapies
Jun 8, 2021 · Bayer recently entered into a pharma acquisition deal with Noria Therapeutics and PSMA Therapeutics to expand its prostate cancer therapies pipeline.See details»
Noria Therapeutics - Products, Competitors, Financials, Employees ...
Noria Therapeutics develops diagnostic and therapeutic radiopharmaceutical agents based on its proprietary Trillium structural chemistry and its proprietary MacroPA radioisotope chelate …See details»
PSMA Therapeutics - Crunchbase Company Profile & Funding
PSMA Therapeutics is a subsidiary of Noria to advance the platform of prostate-specific membrane antigen (PSMA) targeting radiotherapeutics.See details»
Noria Therapeutics Company Profile 2024: Valuation, Investors ...
Manufacturer and developer of targeted therapeutic and imaging radiopharmaceuticals (alpha-emitting) for use in oncology. The company's drug is used for the treatment of metastatic …See details»